Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) EPS (Basic) (2016 - 2025)

Seres Therapeutics' EPS (Basic) history spans 11 years, with the latest figure at $0.94 for Q3 2025.

  • For Q3 2025, EPS (Basic) rose 114.05% year-over-year to $0.94; the TTM value through Sep 2025 reached $18.1, up 211.94%, while the annual FY2024 figure was -$0.81, 8.99% up from the prior year.
  • EPS (Basic) for Q3 2025 was $0.94 at Seres Therapeutics, up from -$2.29 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $15.69 in Q4 2024 and bottomed at -$6.69 in Q3 2024.
  • The 5-year median for EPS (Basic) is -$0.54 (2021), against an average of -$0.12.
  • The largest YoY upside for EPS (Basic) was 4654.55% in 2024 against a maximum downside of 1300.0% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$0.54 in 2021, then decreased by 0.0% to -$0.54 in 2022, then surged by 161.11% to $0.33 in 2023, then skyrocketed by 4654.55% to $15.69 in 2024, then plummeted by 94.01% to $0.94 in 2025.
  • Per Business Quant, the three most recent readings for MCRB's EPS (Basic) are $0.94 (Q3 2025), -$2.29 (Q2 2025), and $3.76 (Q1 2025).